首页> 美国卫生研究院文献>BMC Cancer >Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) a novel histone deacetylase inhibitor for the treatment of thyroid cancer
【2h】

Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) a novel histone deacetylase inhibitor for the treatment of thyroid cancer

机译:新型组蛋白脱乙酰基酶抑制剂N-羟基-7-(2-萘硫基)庚酮(HNHA)对甲状腺癌的潜在抗癌作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThyroid cancer has been indicated to have a higher global proportion of DNA methylation and a decreased level of histone acetylation. Previous studies showed that histone gene reviser and epigenetic changes role significant parts in papillary and anaplastic thyroid cancer tumorigenesis. The goal of this research was to study the endoplasmic reticulum (ER) stress-mediated actions of the dominant histone deacetylase (HDAC) inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide (HNHA), in thyroid cancer and to explore its effects on apoptotic cell death pathways.
机译:背景技术已经表明甲状腺癌具有较高的整体DNA甲基化比例和降低的组蛋白乙酰化水平。先前的研究表明,组蛋白基因修饰和表观遗传变化在甲状腺乳头状和间变性甲状腺癌的肿瘤发生中起重要作用。这项研究的目的是研究内质网(ER)应激介导的组蛋白去乙酰化酶(HDAC)抑制剂N-羟基-7-(2-萘硫基)肝素(HNHA)在甲状腺癌中的作用并探索它对凋亡细胞死亡途径的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号